Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong growth in key business areas like trauma and neuromonitoring, and an increase in adjusted gross profit. Despite a decline in enabling technologies revenue, the company shows resilience and strategic focus on product development and market expansion. The Q&A section indicates analysts' confidence in the management's strategy, despite some uncertainties. The reaffirmation of revenue guidance and positive developments in product portfolio and international markets support a positive sentiment, likely leading to a stock price increase.
Sales $769 million, growing 22.9% year-over-year. Growth driven by U.S. Spine business, international spine, trauma, and neuromonitoring.
Non-GAAP Diluted Earnings Per Share $1.18, growing 42.6% year-over-year. Growth attributed to revenue growth, operational synergies, and Nevro acquisition.
Free Cash Flow $213.9 million, a record for the third quarter. Growth driven by operational efficiencies and revenue growth.
Base Business Revenue $669.8 million, growing 7% as reported and 7.1% day adjusted year-over-year. Growth driven by U.S. and international spine businesses.
Nevro Business Revenue $99.3 million, contributing to overall growth. Sequential growth of 4.9% from the previous quarter.
Adjusted EBITDA Margins (Base Globus Business) 35.3%, growing 435 basis points year-over-year. Growth driven by operational leverage and cost synergies.
Adjusted EBITDA Margins (Nevro Business) 16.2%, showing improvement from negative margins in prior quarters.
U.S. Spine Business Revenue Growth of 9.6% year-over-year. Growth driven by competitive recruiting and product portfolio expansion.
Enabling Technologies Revenue $28 million, declining 27% year-over-year. Decline attributed to lower sales of EGPS systems.
International Spine Business Revenue Growth of 5.6% as reported and 6% day adjusted year-over-year. Growth driven by markets in EMEA, Asia Pacific, and Latin America.
Trauma Business Revenue Growth of 17.2% year-over-year. Growth driven by overcoming manufacturing challenges and portfolio expansion.
Neuromonitoring Business Revenue Growth of 15.8% year-over-year. Growth attributed to overcoming reimbursement headwinds from mid-2024.
Adjusted Gross Profit 68.1%, up from 66.5% year-over-year. Growth driven by favorable sales mix and synergy execution.
Operating Cash Flow $249.7 million, driven by sales growth and working capital improvements.
ExcelsiusXR launch: Introduced a wearable extended reality navigation headset to enhance surgeon focus and workflow ergonomics.
ExcelsiusGPS instruments: Received FDA 510(k) clearance for new instruments compatible with interbody fusion devices, enhancing the Excelsius platform.
ANTHEM plating line expansion: Launched a comprehensive elbow plating system, achieving 80%+ portfolio match with competitors.
Eflex robotic system: Demonstrated ease of use and accuracy in TKA procedures, with plans to expand procedural applications to hip by 2026.
U.S. Spine business: Achieved 9.6% growth, marking 32 consecutive weeks of growth and strong competitive recruiting.
International Spine business: Grew 5.6% as reported, with notable contributions from EMEA, Asia Pacific, and LatAm regions.
Trauma business: Delivered 17.2% growth, marking its highest quarterly revenue since inception.
Nevro acquisition impact: Contributed $99.3 million in revenue, showing sequential growth and integration progress.
Profitability improvements: Adjusted gross margins and EBITDA margins improved significantly, with base Globus business achieving 35.3% EBITDA margin.
Free cash flow: Generated a record $213.9 million in Q3, driven by operational efficiencies and synergy realization.
Capital allocation: Repurchased $40 million in shares during Q3, totaling $256 million year-to-date.
Market penetration strategy: Focused on surgeon conversions, sales force expansion, and operational excellence to drive growth.
Nevro integration: Achieved accretive earnings in 2025, earlier than expected, through cost structure optimization and sales growth.
Capital placement strategy: Enhanced flexibility in capital deal structures to drive spinal implant growth and operationalize capital acquisition.
Enabling Technologies revenue decline: Revenue from Enabling Technologies declined by 27% compared to the prior year quarter, primarily due to lower sales of EGPS systems. This indicates challenges in closing sales at the same pace as in previous years, which could impact overall revenue growth.
International supply chain constraints: Supply chain prioritization for the U.S. market has impacted inventory availability in international markets, potentially limiting growth opportunities in these regions.
Litigation charges: The company incurred onetime net charges for estimated litigation of $28.3 million, which increased SG&A expenses and could pose financial risks if such charges recur.
Nevro integration challenges: While progress has been made, integration activities for the recently acquired Nevro business are ongoing, with potential risks related to supply chain centralization and production activities.
Decline in enabling technology sales: Lower enabling technology sales of $10.3 million were noted, which could affect the company's ability to maintain its competitive edge in this segment.
Capital acquisition challenges: The company is facing challenges in operationalizing capital acquisition processes, moving away from traditional CapEx models, which could delay capital placements and impact implant sales growth.
R&D expense reduction: Synergy actions have led to reduced R&D expenses, which, while improving short-term financials, could impact long-term innovation and product development.
International growth limitations: Despite growth in international markets, supply chain constraints and prioritization of U.S. inventory could limit the ability to fully capitalize on international opportunities.
Revenue Guidance: The company has updated its 2025 net sales guidance to be in the range of $2.86 billion to $2.9 billion, an increase from the previous range of $2.8 billion to $2.9 billion. This implies growth over 2024 ranging from 13.5% to 15.1%.
Earnings Per Share (EPS) Guidance: The 2025 fully diluted non-GAAP earnings per share guidance has been revised to between $3.75 and $3.85, up from the previous range of $3 to $3.30. This implies growth over 2024 ranging from 23.2% to 26.5%.
Gross Profit Margin: For 2025, the company expects total adjusted gross profit to be in the range of 67% to 68% of consolidated revenue.
Research and Development (R&D) Expenses: For 2025, R&D expenses are expected to be in the range of 5% to 5.5% of consolidated revenue.
Tax Rate: The full-year non-GAAP tax rate is expected to be approximately 24% to 25%.
Capital Allocation Strategy: The company plans to prioritize internal investments in product development, manufacturing, and sales infrastructure, while continuing share repurchases and evaluating complementary M&A opportunities.
Nevro Business Outlook: The Nevro business is now expected to be accretive to earnings in fiscal year 2025, earlier than the previous expectation of the second year of operations.
International Market Growth: The company sees long-term potential for international markets to grow revenue in the 10% to 15% range.
Trauma Business Growth: The trauma business is expected to continue its growth trajectory, supported by investments in manufacturing and product portfolio expansion.
Enabling Technologies Outlook: The company remains optimistic about the Enabling Technologies business, with a strong pipeline and plans to expand capital placement and operationalize capital acquisition models.
Share Repurchase Program: We remained active with share repurchases, spending $40 million during the quarter, bringing our year-to-date repurchases to $256 million. Since 2020, share repurchases have been an important part of the Globus capital allocation strategy. From 2020 through the third quarter of 2025, we've spent $815 million to repurchase 14.5 million shares at an average price of $56. On average, we've spent $136 million per year to repurchase 2.4 million shares. Since Q3 2023, we repurchased $566 million or 9.5 million shares, representing approximately 1/4 of the deal dilution. Share repurchases remain an integral part of our capital allocation strategy as we seek to first prioritize internal investment in innovative product development efforts, build sets for our sales personnel across the globe and increase our manufacturing footprint through CapEx. Secondarily, we seek to opportunistically repurchase shares as we demonstrate our confidence in the business and our commitment to creating long-term value for our shareholders.
The earnings call reveals strong financial performance, product development, and market strategy, with positive growth in revenue and free cash flow. The Q&A highlights optimism in AI integration and market expansion, despite some uncertainties in monetization guidance. The reaffirmed revenue guidance and robust pipeline support a positive sentiment. The lack of specific guidance on certain metrics is a minor concern, but overall, the company's strategic initiatives and operational improvements suggest a positive outlook.
The earnings call reveals strong growth in key business areas like trauma and neuromonitoring, and an increase in adjusted gross profit. Despite a decline in enabling technologies revenue, the company shows resilience and strategic focus on product development and market expansion. The Q&A section indicates analysts' confidence in the management's strategy, despite some uncertainties. The reaffirmation of revenue guidance and positive developments in product portfolio and international markets support a positive sentiment, likely leading to a stock price increase.
The earnings call reveals mixed signals: strong financial metrics and operational improvements are offset by decreased EPS guidance and management's reluctance to provide specifics on future performance. The acquisition of Nevro and new product launches are positive, but the uncertain outlook and integration challenges temper optimism. The Q&A session indicated cautious optimism but lacked clarity on key financial metrics. With no market cap data, the neutral sentiment reflects a balanced view of potential short-term market reaction.
The earnings call reflects strong financial performance with record revenue and cash flow, improved net income, and robust guidance post-acquisition. Despite some concerns in international revenue and enabling technologies, management's confidence and strategic focus on synergies and internal investments are promising. The Q&A reveals management's optimism and strategic clarity, despite avoiding specific details on some metrics. The acquisition and revenue guidance are expected to positively impact the stock, and the company's proactive measures in mitigating risks suggest a positive sentiment, likely resulting in a 2% to 8% stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
